Superseded public profile

Not FDA-approved↗Safety records↗↗

Superseded · version 2: Epitalon↗

Related names recorded in this version: AEDG, Epithalon↗

A synthetic tetrapeptide discussed in FDA briefing material for a 2026 pharmacy-compounding advisory-committee meeting.↗↗

This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.
Correction · September 15, 2026

We narrowed the status wording to what the dated FDA briefing establishes. A briefing prepared for an advisory process does not establish the current absence of a later final decision. Related substance identities remain distinct. 1

What this version reported

FDA's July 2026 briefing evaluates epitalon free base and acetate and distinguishes the tetrapeptide from epithalamin, a pineal-gland extract. The briefing is an advisory-process assessment, not a final regulatory determination.↗

Organizations named in cited records:
  • U.S. Food and Drug Administration↗↗

Sources for this version

  1. 1
    FDA briefing document for epitalon ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  2. 2
    July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026